AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
10.64
-0.68 (-6.01%)
At close: Apr 28, 2026, 4:00 PM EDT
10.11
-0.53 (-4.98%)
After-hours: Apr 28, 2026, 4:20 PM EDT
AgomAb Therapeutics NV Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2019 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 |
| Cost of Revenue | - | - | - | - | 2.89 | |
| Gross Profit | - | - | - | - | -2.89 | |
| Selling, General & Admin | 12.79 | 10.13 | 6.1 | 4.51 | 0.2 | |
| Research & Development | 48.88 | 39.31 | 26.31 | 19.42 | - | |
| Other Operating Expenses | -2.39 | -1.42 | -1.22 | -1.3 | 0 | |
| Operating Expenses | 59.28 | 48.02 | 31.19 | 22.63 | 0.2 | |
| Operating Income | -59.28 | -48.02 | -31.19 | -22.63 | -3.09 | |
| Interest Expense | -0.13 | -0.07 | -0.03 | -0.05 | -0.04 | |
| Interest & Investment Income | 1.72 | 1.22 | 0.25 | 0.07 | 0.03 | |
| Currency Exchange Gain (Loss) | - | -0.23 | 0.01 | -0.09 | - | |
| Other Non Operating Income (Expenses) | -4.86 | 0.84 | 18.96 | 11.89 | - | |
| Pretax Income | -62.55 | -46.26 | -12.01 | -10.81 | -3.1 | |
| Income Tax Expense | - | 0 | -0.62 | -2.66 | -0.05 | |
| Net Income | -62.55 | -46.27 | -11.39 | -8.14 | -3.05 | |
| Preferred Dividends & Other Adjustments | - | 11.58 | 7.89 | 5.42 | - | |
| Net Income to Common | -62.55 | -57.85 | -19.28 | -13.56 | -3.05 | |
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | - | |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | - | |
| Shares Change (YoY) | 2064.50% | - | - | - | - | |
| EPS (Basic) | -115.59 | -2314.04 | -771.28 | -542.56 | - | |
| EPS (Diluted) | -115.59 | -2314.04 | -771.28 | -542.56 | - | |
| Free Cash Flow | -51.75 | -47.5 | -24.59 | -18.97 | - | |
| Free Cash Flow Per Share | -95.63 | -1900.12 | -983.68 | -758.68 | - | |
| EBITDA | -59.06 | -47.97 | -31.09 | -22.61 | - | |
| D&A For EBITDA | 0.22 | 0.06 | 0.1 | 0.02 | - | |
| EBIT | -59.28 | -48.02 | -31.19 | -22.63 | -3.09 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.